History
A list of downloadable documents created during development.
Background information
Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: equality impact assessment
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination
-
-
-
Patient Access Scheme
-
Patient Access Scheme submitted by Merck Sharpe & Dohme (MSD) (PDF 382 KB)
-
-
-
Additional data request
-
NICE request to the manufacturer for additional data (PDF 131 KB)
-
Manufacturer's response to NICE's request for additional data (PDF 218 KB)
-
-
-
-
Consultee and commentator comments on the ACD
-
-
-
-
-
-
-
-
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: evaluation report
-
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: clarification
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer's response to clarification
-
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE clarification letters
-
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: non-manufacturer submissions
-
-
-
-
-
-
-
-
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert written personal statements
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final matrix
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
-